Table 3.
Entry | Name | R1 | R2 | R3 | X | KOR 1 % | MOR 1 % | DOR 1 % | BZR 1 % |
KOR (Ki, nM) |
BZR (Ki, nM) |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | GL-I-81 | HC≡C | iPr | (S) | C-F | 93 | 64 | 25 | 83 | 127 | 839 |
2 | MP-IV-010 | HC≡C | iPr | (R) | C-F | 94 | 33 | 5 | 64 | 145 | 814 |
3 | GL-I-66 | HC≡C | Et | (S) | C-F | 92 | 28 | 2 | 80 | 212 | 654 |
4 | GL-I-65 | HC≡C | Me | (S) | C-F | 88 | 2 | 7 | 79 | 222 | 1147 |
5 | GL-IV-03 | c-Pr | Et | (R) | C-F | 91 | 25 | 67 | 65 | 232 | n.d. |
6 | GL-III-60 | Br | Me | (R) | C-F | 87 | 26 | 18 | 100 | 232 | 784 |
7 | MP-IV-004 | HC≡C | Me | (R) | C-F | 86 | 7 | 10 | 63 | 444 | 1079 |
8 | GL-II-54 | HC≡C | Et | (R) | N | 80 | 0 | 0 | 66 | 504 | 2037 |
9 | GL-III-63 | c-Pr | Me | (R) | C-F | 78 | 8 | 31 | 28 | 678 | - 2 |
10 | GL-III-64 | c-Pr | Me | (R) | N | 60 | 7 | 14 | 92 | 2048 | 1490 |
11 | MP-III-085 | HC≡C | Me | H | N | 40 | 0 | 0 | 82 | - 2 | 357 |
12 | MP-III-080 | HC≡C | Et | H | N | 47 | 0 | 0 | 88 | - 2 | 303 |
1 Percent inhibition at 10,000 nM, 2 dose response was carried out only for compounds with an inhibition of >50%, n.d. = not determined.